|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
ethyl eicosapentaenoic acid
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:C10AX06
|
|
gptkbp:brand
|
gptkb:Vascepa
|
|
gptkbp:CASNumber
|
86227-47-6
|
|
gptkbp:chemicalFormula
|
C22H34O2
|
|
gptkbp:contraindication
|
hypersensitivity to icosapent ethyl
|
|
gptkbp:discoveredBy
|
gptkb:Amarin_Corporation
|
|
gptkbp:drugClass
|
omega-3 fatty acid derivative
|
|
gptkbp:eliminationHalfLife
|
89 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
icosapent ethyl
|
|
gptkbp:indication
|
reduce risk of cardiovascular events in adults with elevated triglyceride levels and established cardiovascular disease or diabetes and other risk factors
adjunct to diet to reduce triglyceride levels
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Amarin_Corporation
|
|
gptkbp:mechanismOfAction
|
increases triglyceride clearance
reduces hepatic VLDL-TG synthesis/secretion
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
644102
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:atrial_fibrillation
bleeding
|
|
gptkbp:UNII
|
9656LZ67F8
|
|
gptkbp:usedFor
|
hypertriglyceridemia
cardiovascular risk reduction
|
|
gptkbp:bfsParent
|
gptkb:Vascepa
|
|
gptkbp:bfsLayer
|
8
|